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Abstract
Background: Measuring quality of life in breast cancer patients is of importance in assessing
treatment outcomes. This study examined the impact of breast cancer diagnosis and its treatment
on quality of life of women with breast cancer.
Methods: This was a prospective study of quality of life in breast cancer patients. Quality of life
was measured using the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC QLQ-C30) and its breast cancer supplementary measure (QLQ-BR23)
at three points in time: baseline (pre diagnosis), three months after initial treatment and one year
after completion of treatment (in all 18 months follow-up). At baseline the questionnaires were
administered to all suspected identified patients while both patients and the interviewer were blind
to the final diagnosis. Socio-demographic and clinical data included: age, education, marital status,
disease stage and initial treatment. Repeated measure analysis was performed to compare quality
of life differences over the time.
Results: In all, 167 patients diagnosed with breast cancer. The mean age of breast cancer patients
was 47.2 (SD = 13.5) years and the vast majority (82.6%) underwent mastectomy. At eighteen
months follow-up data for 99 patients were available for analysis. The results showed there were
significant differences in patients' functioning and global quality of life at three points in time (P <
0.001). Although there were deteriorations in patients' scores for body image and sexual
functioning, there were significant improvements for breast symptoms, systematic therapy side
effects and patients' future perspective (P < 0.05).
Conclusion: The findings suggest that overall breast cancer patients perceived benefit from their
cancer treatment in long-term. However, patients reported problems with global quality of life,
pain, arm symptoms and body image even after 18 months following their treatments. In addition,
most of the functional scores did not improve.
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Background
Measuring quality of life in breast cancer patients has been
the focus of clinical practice and research in recent dec-
ades and is of importance in assessing treatment out-
comes [1,2]. This is partly due to the increasing number of
breast cancer patients. Statistics show that each year there
is over 1.1 million newly diagnosed women with breast
cancer worldwide and 410,000 women die from the dis-
ease [3]. On the other hand improvement in early detec-
tion and treatment of breast cancer has led to longer
survival of these patients. Also breast cancer affects
women's identities and therefore studying quality of life
in women who lose their breasts is vital. In addition, it is
believed that women play an important role in family.
When a woman develops breast cancer all family mem-
bers may develop some sort of illnesses [4]. Thus the issue
of 'survivorship' now has become an important topic in
breast cancer care that demands the investigation of long-
term effects of breast cancer diagnosis and its treatments
[5].
The time of diagnosis, initial stages of adjuvant treatment
course and the months immediately following the end of
adjuvant treatment are transition times of poor adjust-
ment and decreased quality of life in breast cancer patients
[6,7]. Studies have shown that decreased health-related
quality of life as a result of chemotherapy side effects may
predict early treatment discontinuation in patients with
breast cancer [8]. On the other hand studies on post-treat-
ment adjustment of breast cancer survivors demonstrated
that breast cancer patients might enjoy from a good qual-
ity of life [9].
This study empirically investigated the impact of breast
cancer diagnosis and its treatments on quality of life of
patients with breast cancer in an eighteen months follow-
up assessment. It was thought measuring quality of life at
baseline (before the final diagnosis of breast cancer was
made) would provide an appropriate basis for investigat-
ing of quality of life changes over time.
Methods
Design
This was a prospective study of quality of life in breast can-
cer patients. The study was conducted in Imam Khomeini
hospital during a one complete calendar year. Imam Kho-
meini hospital is the biggest teaching hospital in Tehran,
affiliated to Tehran University of Medical Sciences. Annu-
ally about 600 to 700 both newly diagnosed and follow-
up breast cancer patients are treated in Imam hospital.
Imam hospital is a referral centre for most cancer patients
from Tehran and other provinces. Medical consultants
identified newly suspected breast cancer patients from
May 2002 to May 2003. All patients were interviewed at
this baseline stage. At baseline both patients and the inter-
viewer were blind to the final diagnosis. It was assumed
that being blind to the final diagnosis would provide
more precise information on quality of life data. Women
with confirmed histological diagnosis of breast cancer
were further followed-up. There were no restrictions on
patient selection with regard to histology of breast cancer,
disease stage and demographic characteristics. First fol-
low-up was scheduled three months after initial treatment
and the second assessment was made one year following
completion of the treatment course (18 months after pre-
diagnosis stage). The course of second follow-up was
completed on December 2004. Patients with progression
and the end-stage cases were not followed-up. Socio-
demographic data included age, education and marital
status. Clinical data consisting of disease stage and initial
management were extracted from case records. The Ira-
nian Center for Breast Cancer approved the study and all
interviews were carried out with patients' permissions.
Measures
Quality of life was measured using the EORTC QLQ-C30
and its supplementary breast cancer questionnaire (QLQ-
BR23). The EORTC QLQ-C30 is a well-known instrument
for measuring quality of life in cancer patients and con-
tains 30 items that measures five functional scales, global
quality of life and several cancer related symptoms. The
QLQ-BR23 is a specific questionnaire containing 23 items
measuring functioning and symptoms related to breast
cancer. The questionnaires were administered at three
points in time: baseline, after initial treatment and one
year after completion of treatment. The psychometric
properties of the Iranian version of both questionnaires
are well documented [10,11].
Analysis
Data were analyzed using SPSS-13 and restricted to the
patients that their quality of life data were available. Nor-
mality of data were examined and although distributions
were slightly skewed but all skewness values were less
than one allowing us to perform repeated measure
ANOVA to examine changes in quality of life measures
across three points in time. The P value of equal or less
than 0.01 was considered significant. For comparing cate-
gorical data, chi-squared was used.
Results
Patients' characteristics
In all, 316 suspected breast cancer patients were inter-
viewed at baseline (pre-diagnosis stage). Of these, 167
patients with breast cancer were followed-up. The mean
age of breast cancer patients was 47.2 (SD = 13.5) years;
most were married (69.4%), and have had primary or sec-
ondary education (66.5%). According to case records the
vast majority of the cases (82.6%) underwent mastectomy
and the disease stage was as follows: 17.4% local, 45.5%BMC Cancer 2008, 8:330 http://www.biomedcentral.com/1471-2407/8/330
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loco-regional and 37.1% metastasis. The demographic
and clinical characteristics of the sample at three points in
time are shown in Table 1. At first follow-up 150 breast
cancer patients were re-interviewed and the remaining 17
patients were excluded from the study. Of these 17
patients, 6 patients were refused to be re-interviewed, 1
was terminally ill, 8 were lost and 2 were dead.
At the second follow-up 99 patients were interviewed and
the remaining 51 patients were excluded from the study.
Reasons for attrition were: dislike (n = 25), loss to follow
(n = 10) and death (n = 16). Analysis showed that women
who completed the entire study differed on age and edu-
cational level from the sample that dropped out of the
study.
Functioning and global quality of life
Table 2 shows patients' functioning and global quality of
life as measured by the EORTC QLQ-C30. Physical func-
tioning improved over time while there was deterioration
in most of the other functioning scales.
Physical functioning was increased by 5.8 point after 18
months follow-up, which could be regarded remarkable
improvement. Global quality of life scores showed a fluc-
tuated picture: 59.2 at baseline, 71.3 at 3-months follow-
up and 32.0 at third assessment.
Symptoms
The analysis showed that in all measures there were statis-
tically significant differences in patients' symptom scores
(Table 3). Compared to the baseline and three months
assessments, symptoms including fatigue, pain and dysp-
nea were increased at 18 months follow-up assessment.
Fatigue as the most disturbing disease- and treatment-
related symptom was increased sharply both at 3-months
assessment and 18-months follow-up: 17.0 at baseline,
31.0 at 3-months follow-up and 36.0 at 18 months fol-
low-up. Also at 3 and 18 months follow-ups there were
higher levels of financial difficulties than baseline (22.1
and 23.1 versus 17.7).
Breast cancer specific scores
Breast cancer patients' quality of life scores as measured by
the EORTC QLQ-BR23 are shown in Table 4. Except for
future perspective, there were significant deteriorations in
Table 1: Demographic and clinical characteristics of the study sample at three time points
Baseline assessment (n = 167) 3 months follow-up (n = 150) 18 months follow-up (n = 99) P*
No (%) No (%) No (%)
Age groups (years) 0.03
24–34 33 (19.8) 29 (19.3) 18 (18.2)
35–44 46 (27.5) 40 (26.7) 29 (29.3)
45–54 39 (23.4) 38 (25.3) 30 (30.2)
55–64 28 (16.8) 26 (17.3) 15 (15.2)
64 > 21 (12.5) 17 (11.4) 7 (7.1)
Mean (SD) 47.2 (13.5) 47.4 (13.3) 46.4 (12.5)
Range 24–81 24–81 24–81
Educational level 0.05
Illiterate 38 (22.8) 34 (22.7) 17 (17.2)
Primary 78 (46.7) 71 (47.3) 45 (45.5)
Secondary 33 (19.8) 29 (19.3) 25 (25.2)
College/university 18 (10.7) 16 (10.7) 12 (12.1)
Marital status 0.4
Single 15 (9.0) 13 (8.7) 11 (11.1)
Married 116 (69.4) 105 (70.0) 67 (67.7)
Widowed 36 (21.6) 32 (21.3) 21 (21.2)
Disease stage 0.4
Local 29 (17.4) 25 (16.7) 18 (18.2)
Loco-regional 76 (45.5) 71 (47.3) 48 (48.5)
Metastasis 62 (37.1) 54 (36.0) 33 (33.3)
Initial management 0.09
Mastectomy 138 (82.6) 125 (83.3) 84 (84.8)
Conservative surgery 15 (9.0) 14 (9.3) 11 (11.1)
Chemotherapy 11 (6.6) 10 (6.7) 4 (4.1)
Best supportive care 3 (1.8) 1 (0.7) 0 (0.0)
*χ2 testBMC Cancer 2008, 8:330 http://www.biomedcentral.com/1471-2407/8/330
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all other patients' functioning scores over time compared
to the baseline assessment.
Decreased body image was observed at 3 and 18 months
follow-ups (61.4 and 60.8 respectively) compared to the
baseline assessment (86.2).
Comparing the baseline assessment, an increased level of
arm symptoms was observed at 3 months follow-up
(17.2) that continued to be persistent at 18 months fol-
low-up (24.8).
Discussion
This study provided data on health-related quality of life
of 99 breast cancer patients through an eighteen months
follow-up using standard quality of life measures. The
results showed that physical functioning was improved
following one year after the completion of breast cancer
treatment (Table 2). It is argued that most aspects of
health-related quality of life including physical health will
recover after adjuvant treatment course ends and no resid-
ual effects will exist in longer periods for the majority of
patients [12-14].
Patients rated their emotional functioning lower at 18
months follow-up than baseline and 3 months assess-
ments. Similarly, the patients at 18 months follow-up
reported decreased global quality of life. A study on dis-
tress and quality of life 3 months following treatment for
breast cancer patients showed that there were moderate
distress due to fear of cancer recurrence and resuming nor-
mal life. However, the same study found that quality of
life, as measured by the SF-36 questionnaire, was
improved in most areas including physical functioning,
bodily pain and vitality [9]. It is believed that 1 to 3
months following adjuvant treatment, as a transition
period, is a time of disruption and increased distress
[7,15]. There might be several explanations why this post-
treatment period is a particularly distressing time for
breast cancer patients. Remaining the physical effects of
treatment such as fatigue, hair loss, lymph edema [16],
leaving their routine connection with their medical treat-
ment team [7] and loss of support from family and friends
who may not realize patients' cancer-related physical and
psychological issues [16] are among the most important
reasons. A qualitative study among breast cancer patients
who had completed their treatment investigated their
health care needs. The findings indicated that these
women continue to experience a variety of physical and
psychological symptoms and need information and sup-
port [17].
Table 2: Breast cancer patients' pre-diagnosis and follow-ups functioning and global quality of life scores as measured by the EORTC 
QLQ-C30* (n = 99)
Baseline assessment 3 months follow-up 18 months follow-up P
Functioning Mean (SD) Mean (SD) Mean (SD)
Physical functioning 68.7 (24.9) 66.8 (20.6) 72.6 (19.7) <0.001
Role functioning 69.7 (27.1) 66.0 (24.5) 69.8 (30.4) <0.001
Emotional functioning 59.4 (23.5) 61.3 (24.1) 55.5 (27.6) <0.001
Cognitive functioning 79.4 (20.1) 74.2 (19.2) 74.4 (20.6) <0.001
Social functioning 85.0 (18.0) 82.5 (20.9) 79.3 (25.5) <0.001
Global quality of life 59.2 (31.8) 71.3 (25.6) 32.0 (30.2) <0.001
*The higher values indicate higher level of functioning and quality of life, min: 0, max: 100
Table 3: Breast cancer patients' pre-diagnosis and follow-ups symptoms scores as measured by the EORTC QLQ-C30* (n = 99)
Baseline assessment 3 months follow-up 18 months follow-up P
Symptoms Mean (SD) Mean (SD) Mean (SD)
Fatigue 17.0 (19.4) 31.0 (25.4) 36.0 (21.8) <0.001
Nausea and vomiting 1.7 (7.3) 29.3 (30.5) 2.5 (10.7) <0.001
Pain 4.5 (9.7) 4.5 (10.6) 15.3 (21.0) <0.001
Dyspnea 5.7 (14.3) 8.7 (16.2) 14.8 (21.9) <0.001
Sleep difficulties 27.5 (30.2) 25.2 (30.3) 26.9 (27.3) <0.001
Appetite loss 20.9 (29.2) 35.7 (32.4) 6.7 (18.4) <0.001
Constipation 2.3 (9.8) 9.1 (19.5) 10.1 (19.9) <0.001
Diarrhea 0.33 (3.3) 2.0 (9.3) 1.0 (5.7) 0.003
Financial difficulties 17.7 (25.8) 22.1 (27.0) 23.1 (28.5) <0.001
*The higher values indicate a greater degree of symptoms, min: 0, max: 100BMC Cancer 2008, 8:330 http://www.biomedcentral.com/1471-2407/8/330
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In this study patients reported poor social functioning fol-
lowing completion of breast cancer treatment. Similarly
studies have found that breast cancer survivors suffer from
poor social functioning [18,19].
Decreased cognitive functioning was observed at 3
months assessment that continued to be persistent at 18
months follow-up. Long-term (1 to 10 years) cognitive
impairment in patients with breast cancer after their
chemotherapy treatment has been reported [20,21]. It is
argued that the observed impairment occurs most often in
attention, learning and processing speed and is not attrib-
uted to demographic characteristics, clinical features and
baseline level of cognitive function [20].
There were elevated levels of fatigue, pain and dyspnea
(Table 3) and arm symptoms (Table 4) at 18 months fol-
low-up assessment. This is consistent with the findings of
similar studies that reported women with breast cancer
experienced substantial complaints as a result of cancer
and its treatment [22-24]. A review on adjuvant systemic
therapy for early stage breast cancer reported that except
for vasomotor symptoms all the other detrimental effects
of these treatments are transient and would rapidly be
removed at the end of the treatment courses [2].
Except for future perspective all the other breast cancer
specific functioning including body image, sexual func-
tioning and sexual enjoyment decreased at eighteen
months follow-up assessment. Sexual dysfunction is a
symptom that may occur as a result of premature meno-
pause following adjuvant systemic therapy in breast can-
cer patients [2].
Most patients in this study were diagnosed with advanced
disease (loco-regional 45.5%, and metastasis 37.1%).
Also mastectomy was the treatment of choice for 82.6% of
patients and just a small number of them received breast
conservation (9.0%). A study on cancer practice by gen-
eral surgeons in Iran showed that Iranian surgeons do not
routinely perform breast conserving surgery as the first
treatment modality for breast cancer patients [25]. Unfor-
tunately this is a common situation in Iran and it needs
further attention in order to improve both early diagnosis
and clinical outcomes.
However this study was limited due to its small cohort of
breast cancer patients. Also there was a drop-out-rate of
nearly one third of patients during the follow-up courses.
In addition, patients were relatively young, although stud-
ies have shown that in Iran breast cancer patients present
with advanced stage and they are about 10 years younger
than their western counterparts [26,27]. Furthermore
most of the functional scores did not improve over time
and this is in contradiction to the findings from some
existing literature [28].
Conclusion
The study findings showed that overall breast cancer
patients perceived benefit from their adjuvant treatment.
However sustained problems such as fatigue, pain, sleep
disturbances and arm symptoms were observed. Indeed,
these should be managed by targeted interventional pro-
grams. Also, impaired body image decreased sexual func-
tioning and sexual enjoyment in patients must be
seriously considered in long-term survivors of breast can-
cer to improve their overall quality of life.
Abbreviations
EORTC QLQ-C30: European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire-
Cancer 30; EORTC QLQ-BR23: European Organization
Table 4: Breast cancer patients' pre-diagnosis and follow-ups functioning and symptoms scores as measured by the EORTC QLQ-
BR23* (n = 99)
Baseline assessment 3 months follow-up 18 months follow-up P
Mean (SD) Mean (SD) Mean (SD)
Functioning
Body image 86.2 (18.8) 61.4 (34.4) 60.8 (34.4) <0.001
Sexual functioning 82.3 (22.4) 74.5 (21.9) 67.7 (26.4) <0.001
Sexual enjoyment 51.6 (25.3) 46.6 (25.1) 23.3 (28.8) <0.001
Future perspective 29.9 (29.5) 36.0 (26.4) 36.7 (29.1) <0.001
Symptoms+
Arm symptoms 7.7 (13.3) 17.2 (16.5) 24.8 (20.2) <0.001
Breast symptoms 15.6 (15.0) 10.2 (14.0) 6.5 (9.7) <0.001
Systematic therapy side effects 15.7 (11.8) 29.2 (17.5) 18.0 (13.7) <0.001
Upset by hair loss 0.00 38.9 (38.9) 50.0 (18.2) 0.003
* Scores range from 0 to 100, with higher scores representing a higher level of functioning.
+ Scores range from 0 to 100, with higher scores representing a higher level of symptoms.Publish with BioMed Central    and   every 
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